ENDRA Life Sciences(US:NDRA)2025-11-14 21:24Revenue and Financial Performance - No revenue was generated from the TAEUS technology during the three months ended September 30, 2025, and 2024[110]. - The net loss for the three months ended September 30, 2025, was $1,595,959, an improvement from a net loss of $2,354,090 for the same period in 2024[130]. - Net loss narrowed to $3,858,201 for the nine months ended September 30, 2025, compared to a net loss of $7,358,943 for the same period in 2024[136]. - As of September 30, 2025, the company had an accumulated deficit of $107,296,300 and cash of $794,036[137]. - The company used $3,570,847 of cash in operating activities during the nine months ended September 30, 2025, primarily due to the net loss[140]. Expenses - Research and development expenses decreased by 46% to $432,113 for the three months ended September 30, 2025, compared to $794,444 for the same period in 2024[126]. - Sales and marketing expenses also decreased by 46% to $45,285 for the three months ended September 30, 2025, down from $83,157 in the prior year[127]. - General and administrative expenses increased by 41% to $893,305 for the three months ended September 30, 2025, compared to $631,413 for the same period in 2024[128]. - Research and development expenses decreased by 47% to $1,341,859 for the nine months ended September 30, 2025, compared to $2,552,336 for the same period in 2024[132]. - Sales and marketing expenses decreased by 62% to $183,110 for the nine months ended September 30, 2025, compared to $484,769 for the same period in 2024[133]. - General and administrative expenses decreased by 25% to $2,616,106 for the nine months ended September 30, 2025, compared to $3,483,303 for the same period in 2024[134]. - Other income increased by 134% to $282,874 for the nine months ended September 30, 2025, compared to an expense of $838,535 for the same period in 2024[135]. Financing and Capital Activities - The company closed a private placement on October 15, 2025, raising approximately $4.9 million, primarily to establish its Digital Asset Treasury strategy[109]. - Financing activities provided $1,152,684 in proceeds from issuances of common stock for the nine months ended September 30, 2025[143]. - The company is considering potential financing options, including sales of common stock, to support its commercialization plans and DAT strategy[138]. Future Plans and Strategies - Research and development expenses are expected to continue as the company pursues FDA approval for the NAFLD TAEUS system[113]. - The company plans to incur up to $750,000 of offering proceeds on a pilot validation study for the TAEUS liver device[109]. - The company anticipates continued costs associated with being a public company, including compliance with Nasdaq and SEC requirements[115]. - The company plans to advance the engineering design and development of its TAEUS technology and complete regulatory filings for marketing approval of its NAFLD TAEUS application[146]. - The company purchased 78,863.1 HYPE tokens valued at approximately $3,000,000 as part of its DAT strategy[109].